 "Aurobindo Pharma gains on good Q4 results")
Aurobindo Pharma has moved higher by 5% to Rs 795 on the BSE in noon deals after the company reported 39% year on year (YoY) jump in consolidated net profit at Rs 563 crore for the quarter ended March 2016 (Q4FY16) on the back of healthy growth in net sales. Consolidated revenues grew 19% YoY at Rs 3,747 crore on YoY basis.
Analysts on an average had expected profit of Rs 556 crore on revenues of Rs 3,713 crore for the quarter.
Ebitda (earnings before interest, taxes, depreciation and amortization) margin before forex improved 280 basis points to 23.5% from 20.7%.
“The company’s US formulations contributed 44% to the total revenues, witnessed 24.3% growth YoY in Q4FY16, due to the new launches in the oral and injectable segment and growth in the Natrol business,” Aurobindo Pharma said in a release.
EU formulations, which contributed 22% to the total revenues, registered 9.3% growth YoY during the quarter. The acquired business has seen profitability during the year on the back of increased focus, product pruning and cost efficiencies, it added.
At 01:42 PM, the stock was up 4.5% at Rs 789 on the BSE. A combined 3.23 million shares changed hands on the counter on the BSE and NSE.
Analysts on an average had expected profit of Rs 556 crore on revenues of Rs 3,713 crore for the quarter.
Ebitda (earnings before interest, taxes, depreciation and amortization) margin before forex improved 280 basis points to 23.5% from 20.7%.
“The company’s US formulations contributed 44% to the total revenues, witnessed 24.3% growth YoY in Q4FY16, due to the new launches in the oral and injectable segment and growth in the Natrol business,” Aurobindo Pharma said in a release.
EU formulations, which contributed 22% to the total revenues, registered 9.3% growth YoY during the quarter. The acquired business has seen profitability during the year on the back of increased focus, product pruning and cost efficiencies, it added.
At 01:42 PM, the stock was up 4.5% at Rs 789 on the BSE. A combined 3.23 million shares changed hands on the counter on the BSE and NSE.